Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Decorin-binding receptors and partners comprise a diverse array of cell surface signaling molecules and extracellular matrix (ECM) components that interact with the small leucine-rich proteoglycan (SLRP) decorin. This interactome is primarily defined by decorin's role as a "pan-receptor tyrosine kinase (RTK) inhibitor," where it binds to and antagonizes key receptors such as the epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (Met), and vascular endothelial growth factor receptor 2 (VEGFR2) [1.3.1, 1.5.1]. Upon binding, decorin triggers receptor dimerization, internalization via caveolae, and subsequent lysosomal degradation, thereby suppressing oncogenic signaling pathways [1.3.4, 1.5.1]. Furthermore, decorin acts as a biological reservoir or "sink" for various growth factors, most notably transforming growth factor-beta (TGF-beta), which allows it to modulate fibrotic responses and immune signaling [1.2.1, 1.3.4]. In the tumor microenvironment, these interactions collectively inhibit cell proliferation, angiogenesis, and metastasis while promoting tumor cell mitophagy and endothelial cell autophagy [1.1.3, 1.2.3]. Therapeutic strategies targeting this network include recombinant human decorin and targeted fusion proteins like CAR-decorin, which are being investigated for their potential to treat solid tumors and chronic fibrotic conditions [1.1.3, 1.2.1]. However, the broad nature of these interactions presents challenges, including potential pro-inflammatory effects through Toll-like receptors (TLR2/4) and the risk of interfering with normal tissue repair and growth factor homeostasis [1.2.2, 1.4.1].
Competitive inhibition of growth factor binding, induction of receptor internalization and degradation, sequestration of growth factors (e.g., TGF-beta), and induction of Peg3-dependent autophagy.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Decorin-binding receptors and partners (DCN-BRP).